Paper Details 
Original Abstract of the Article :
Pantoprazole is a proton pump inhibitor that is commonly used in the treatment of peptic ulcer disease (PUD) and metabolized by cytochrome P450 (CYP) enzymes CYP2C19 and CYP3A4. Pantoprazole is a substrate for multi-drug resistance protein 1 (MDR1). Single nucleotide polymorphisms (SNPs) in CYP2C19,...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1111/bcpt.12667

データ提供:米国国立医学図書館(NLM)

A Genetic Odyssey: Exploring the Impact of Polymorphisms on Pantoprazole Metabolism

The [treatment of peptic ulcer disease (PUD)] often involves the use of [proton pump inhibitors] like [pantoprazole]. This study delves into the [genetic variations] that can affect [pantoprazole metabolism] and [Helicobacter pylori eradication]. The researchers investigated the influence of [polymorphisms] in [CYP2C19], [CYP3A4], and [MDR1] on [pantoprazole pharmacokinetics] and [treatment success] in patients with [H. pylori-associated PUD] or [gastritis].

A Genetic Compass: Navigating the Landscape of Polymorphisms

Imagine a caravan crossing a desert with a network of hidden pathways. This study is like a genetic compass, revealing how [polymorphisms] in certain genes can influence the effectiveness of [pantoprazole therapy]. The researchers found that [CYP2C19 polymorphisms] significantly affected [pantoprazole plasma concentrations], suggesting that [genetic testing] could help personalize treatment for patients with [PUD] or [gastritis].

A Journey of Discovery: Implications for PUD and Gastritis Treatment

This study provides valuable insights into the [role of genetics] in [PUD] and [gastritis] treatment. The researchers' findings highlight the potential benefits of [personalized medicine] in optimizing treatment outcomes. Further research is needed to explore the [clinical implications] of these findings and to develop [tailored treatment strategies] based on [genetic profiles].

Dr.Camel's Conclusion

This research is a testament to the power of [personalized medicine] in the realm of [PUD] and [gastritis] treatment. The researchers' discovery of the [influence of genetic variations] on [pantoprazole metabolism] opens up a new frontier for [treatment optimization]. Just as a wise camel adapts to the unique terrain of the desert, we must continue to explore the [genetic landscape] to ensure that each patient receives the most effective and personalized treatment possible.

Date :
  1. Date Completed 2017-02-27
  2. Date Revised 2018-12-11
Further Info :

Pubmed ID

27611887

DOI: Digital Object Identifier

10.1111/bcpt.12667

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.